Arphio and Adalvo Expand Access to Ambrisentan + Tadalafil

15.12.2023

Arphio, in collaboration with Adalvo, is proud to introduce Ambrisentan + Tadalafil Film-Coated Tablets (5mg+20mg, 5mg+40mg, 10mg+40mg), an innovative treatment addressing the urgent unmet needs of patients with Pulmonary Arterial Hypertension.

In a phase 3/4 clinical trial (AMBITION study1) conducted by GlaxoSmithKline and Gilead Sciences, combination therapy of Ambrisentan and Tadalafil demonstrated superior efficacy compared to Ambrisentan or Tadalafil's monotherapy.

The combined brands sold approximately $1Bn globally in 2022, according to IQVIA.

"Collaborating with Adalvo on the development of Ambrisentan + Tadalafil Film-Coated Tablets is a significant milestone. Together, we strive to provide innovative solutions for patients with Pulmonary Arterial Hypertension. This partnership aligns perfectly with Arphio's mission to bring transformative therapies to those in need," stated Dr. Shlomo Sadoun, CEO of Arphio.

"The introduction of Ambrisentan + Tadalafil Film-Coated Tablets is a testament to Adalvo's commitment to addressing critical medical needs. This advanced treatment showcases Adalvo's dedication to advancing healthcare solutions and making a meaningful impact on patients' lives" stated Anil Okay, CEO of Adalvo.

The ongoing collaboration between Arphio and Adalvo ensures a clearly outlined regulatory pathway, securing the delivery of this transformative treatment to those who need it most. To the best of our understanding, Arphio and Adalvo are pioneering as one of the first organisations to offer this combined therapy within the regulated pharmaceutical markets globally.

About Arphio

Arphio is an orphan pharmaceutical company founded on the mission to improve patients access to vital treatments for rare diseases.

We believe that collaboration always yields the best results. That is why we are driven by the conviction that it is only by combining our expertise and global market reach with leading specialists in the development of orphan products that can we make vital treatments for rare diseases available to a broader population worldwide.

Arphio is founded by pharmaceutical professionals with expertise covering all major therapeutic areas and pharmaceutical forms. We are focused on rare disease detection, market access and the supply of orphan drugs internationally.

About Adalvo

Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 125 countries and for over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners.

 With headquarters in Malta, the company has additional offices in more than 17 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals.

We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavors, driven by a deep-rooted passion to making a difference for partners.

The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.

1: AMBITION study sponsored by GlaxoSmithKline in collaboration with Gilead Sciences: https://clinicaltrials.gov/study/NCT01178073